Youqiang Ke

Liverpool, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Experimental treatment efficacy of dmrFABP5 on prostate cancer singly or in combination with drugs in use.

Experimental treatment efficacy of dmrFABP5 on prostate cancer singly or in combination with drugs in use.

Journal: American journal of cancer research

Published: November 27, 2023

FABP5 can substitute for androgen receptor in malignant progression of prostate cancer cells.

FABP5 can substitute for androgen receptor in malignant progression of prostate cancer cells.

Journal: International journal of oncology

Published: September 12, 2023

SBFI26 induces triple-negative breast cancer cells ferroptosis via lipid peroxidation.

SBFI26 induces triple-negative breast cancer cells ferroptosis via lipid peroxidation.

Journal: Journal of cellular and molecular medicine

Published: August 18, 2023

Molecular mechanisms on how FABP5 inhibitors promote apoptosis-induction sensitivity of prostate cancer cells.

Molecular mechanisms on how FABP5 inhibitors promote apoptosis-induction sensitivity of prostate cancer cells.

Journal: Cell biology international

Published: October 12, 2022

Letter to the Editor: Perspectives on mRNA Vaccine Development for Cancer.

Letter to the Editor: Perspectives on mRNA Vaccine Development for Cancer.

Journal: Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research

Published: September 16, 2022

Correction: Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5.

Correction: Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5.

Journal: Oncotarget

Published: August 22, 2020

Inactivated FABP5 suppresses malignant progression of prostate cancer cells by inhibiting the activation of nuclear fatty acid receptor PPARγ.

Inactivated FABP5 suppresses malignant progression of prostate cancer cells by inhibiting the activation of nuclear fatty acid receptor PPARγ.

Journal: Genes & cancer

Published: July 02, 2019

Fatty acid-binding protein 5 (FABP5)-related signal transduction pathway in castration-resistant prostate cancer cells: a potential therapeutic target.

Fatty acid-binding protein 5 (FABP5)-related signal transduction pathway in castration-resistant prostate cancer cells: a potential therapeutic target.

Journal: Precision clinical medicine

Published: June 18, 2019

Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5.

Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5.

Journal: Oncotarget

Published: December 19, 2016

The increased expression of fatty acid-binding protein 9 in prostate cancer and its prognostic significance.

The increased expression of fatty acid-binding protein 9 in prostate cancer and its prognostic significance.

Journal: Oncotarget

Published: June 17, 2016

High expression of Fatty Acid-Binding Protein 5 promotes cell growth and metastatic potential of colorectal cancer cells.

High expression of Fatty Acid-Binding Protein 5 promotes cell growth and metastatic potential of colorectal cancer cells.

Journal: FEBS open bio

Published: August 27, 2015

The cancer-promoting gene fatty acid-binding protein 5 (FABP5) is epigenetically regulated during human prostate carcinogenesis.

The cancer-promoting gene fatty acid-binding protein 5 (FABP5) is epigenetically regulated during human prostate carcinogenesis.

Journal: The Biochemical journal

Published: August 19, 2015

Showing 1-12 of 16

Last Updated: 09/26/2026